Karakas, M., Akın, I., Burdelski, C., Clemmensen, P., Grahn, H., Jarczak, D., . . . Kluge, S. (2022). Single-dose of adrecizumab versus placebo in acute cardiogenic shock (ACCOST-HH): An investigator-initiated, randomised, double-blinded, placebo-controlled, multicentre trial. The lancet. Respiratory medicine, 10(3), . https://doi.org/10.1016/S2213-2600(21)00439-2
Chicago-Zitierstil (17. Ausg.)Karakas, Mahir, et al. "Single-dose of Adrecizumab Versus Placebo in Acute Cardiogenic Shock (ACCOST-HH): An Investigator-initiated, Randomised, Double-blinded, Placebo-controlled, Multicentre Trial." The Lancet. Respiratory Medicine 10, no. 3 (2022). https://doi.org/10.1016/S2213-2600(21)00439-2.
MLA-Zitierstil (9. Ausg.)Karakas, Mahir, et al. "Single-dose of Adrecizumab Versus Placebo in Acute Cardiogenic Shock (ACCOST-HH): An Investigator-initiated, Randomised, Double-blinded, Placebo-controlled, Multicentre Trial." The Lancet. Respiratory Medicine, vol. 10, no. 3, 2022, https://doi.org/10.1016/S2213-2600(21)00439-2.